Activating BRAF alterations at the V600E locus is a well-known driver in pan-cancer and FDA-approved therapeutic targets for colorectal cancer, melanoma, non-small cell lung cancer, and anaplastic thyroid cancer. The gene discussed is BRAF; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.